NCT02272049 Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults
| NCT ID | NCT02272049 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Children's Hospital Medical Center, Cincinnati |
| Condition | Respiratory Disorders |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2014-12 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 300 participants in total. It began in 2014-12 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to evaluate the usefulness of hyperpolarized (HP) 129Xe (xenon) gas MRI for regional assessment of lung function in a normal population of children and adults and in adults and also in children with respiratory compromise due to a variety of diseases.
Eligibility Criteria
Inclusion Criteria: * Ages 6 and up * Participant must be able to hold breath for up to 16 seconds Exclusion Criteria: * History of heart defect * Pregnancy or positive pregnancy test * History of uncontrolled asthma defined for this study as requiring use of rescue inhaler ≥ 2 times in past month * Symptoms of respiratory infection (loose or productive cough or wheeze), chest tightness, or sinus infection within past week * Baseline oximetry at MRI visit of less than 95% on room air or less than 95% on a previously prescribed dosage of oxygen delivered by nasal cannula * Participant is claustrophobic and unable to tolerate the imaging. * Standard MRI exclusions (metal, implants)
Contact & Investigator
Jason C. Woods, PhD
PRINCIPAL INVESTIGATOR
Children's Hospital Medical Center, Cincinnati
Frequently Asked Questions
Who can join the NCT02272049 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, studying Respiratory Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT02272049 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT02272049 currently recruiting?
Yes, NCT02272049 is actively recruiting participants. Contact the research team at Carrie.Stevens@cchmc.org for enrollment information.
Where is the NCT02272049 trial being conducted?
This trial is being conducted at Cincinnati, United States.
Who is sponsoring the NCT02272049 clinical trial?
NCT02272049 is sponsored by Children's Hospital Medical Center, Cincinnati. The principal investigator is Jason C. Woods, PhD at Children's Hospital Medical Center, Cincinnati. The trial plans to enroll 300 participants.